EMERYVILLE, Calif., Sept. 14 /PRNewswire-FirstCall/ -- NovaBay(R)
Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a
clinical stage company developing novel anti-infective compounds for the
treatment or prevention of a wide range of bacterial, viral and fungal
infections, presented in two poster sessions today at the 49th Annual
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in
San Francisco. These two separate laboratory studies of its Aganocide(R)
compounds reveal potent activity in killing bacteria that have developed
resistance to antiseptics and antibiotics and that the compounds demonstrate
rapid bactericidal and anti-biofilm activity in the presence of plasma, serum
or albumin.
